As of November 7, 2026, 2 holders' latest Schedule 13D or 13G filings report owning 5% or more of Marker Therapeutics, Inc. The largest reported stake is New Enterprise Associates 16, L.P.'s, at 9.9%. 5 filings are on record since August 18, 2025 (Schedule 13D/A, November 17, 2025).
Sell to companies like Marker Therapeutics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Holder: New Enterprise Associates 16, L.P. · Percent: 9.9% · SCHEDULE 13D/A
- · Holder: Alyeska Investment Group, L.P. · Percent: 9.9% · SCHEDULE 13G/A
- · Holder: John R. Wilson TTE, John R. Wilson Revocable Trust U/A DTD 08/03/2017 · Percent: 4.96% · SCHEDULE 13D/A
- · Holder: John R. Wilson TTE, John R. Wilson Revocable Trust U/A DTD 08/03/2017 · Percent: 5.1% · SCHEDULE 13D/A
- · Holder: New Enterprise Associates 16, L.P. · Percent: 12.6% · SCHEDULE 13D/A
Marker Therapeutics, Inc. has 5 Schedule 13D or 13G filings on record since 2025-08-18. 2 holders' latest filing reports 5% or more of common stock, par value $0.001 per share. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| New Enterprise Associates 16, L.P. | 9.9% | 1,670,081 | SCHEDULE 13D/A, 2025-11-17 | 2025-11-13 |
| Alyeska Investment Group, L.P. | 9.9% | 1,280,952 | SCHEDULE 13G/A, 2025-11-14 | 2025-09-30 |
| John R. Wilson TTE, John R. Wilson Revocable Trust U/A DTD 08/03/2017 | 4.96% | 641,801 | SCHEDULE 13D/A, 2025-08-20 | 2025-08-19 |
Holding shares or following this stake? See who's behind Marker Therapeutics, Inc. and the warning signs.
Free to see. No signup.
Keep reading
More on Marker Therapeutics, Inc. and the records around it.
Marker Therapeutics, Inc. elsewhere on the record
Companies that share a holder
- New Enterprise Associates 16, L.P. also filed stake reports on 1 other company: Trevi Therapeutics, Inc. (May 2026)
- Alyeska Investment Group, L.P. also filed stake reports on 81 other companies: ABUNDIA GLOBAL IMPACT GROUP, INC. (Aug 2026), Bakkt, Inc. (Aug 2026), BATTALION OIL CORP (Aug 2026)
Watch Marker Therapeutics, Inc.
Get an email when Marker Therapeutics, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Marker Therapeutics, Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Marker Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Marker Therapeutics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
6 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Purpose of Transaction (Item 4)
New Enterprise Associates 16, L.P.
NEA 16 acquired the NEA 16 Shares for investment purposes. Depending on market conditions, its continuing evaluation of the business and prospects of the Issuer and other factors, NEA 16 and the other Reporting Persons may dispose of or acquire additional shares of the Issuer, including shares that may be acquired upon exercise of the Warrants prior to expiration. Except as set forth above, none of the Reporting Persons has any present plans which relate to or would result in: (a) The acquisition by any person of additional securities of the Issuer, or the disposition of securities of the Issuer; (b) An extraordinary corporate transaction, such as a merger, reorganization or liquidation, involving the Issuer or any of its subsidiaries; (c) A sale or transfer of a material amount of assets of the Issuer or any of its subsidiaries; (d) Any change in the present board of directors or management of the Issuer, including any plans or proposals to change the number or term of directors or to fill any existing vacancies on the board; (e) Any material change in the present capitalization or dividend policy of the Issuer; (f) Any other material change in the Issuer's business or corporate structure; (g) Changes in the Issuer's charter, bylaws or instruments corresponding thereto or other actions which may impede the acquisition of control of the Issuer by any person; (h) Causing a class of securities of the Issuer to be delisted from a national securities exchange or to cease …The first part of Item 4 of the SCHEDULE 13D/A filed 2025-11-17; the filing has the rest
John R. Wilson TTE, John R. Wilson Revocable Trust U/A DTD 08/03/2017
The information set forth in Item 4 of Amendment No. 1 is incorporated herein by reference.Item 4 of the SCHEDULE 13D/A filed 2025-08-20
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-08-18 | New Enterprise Associates 16, L.P. | 12.6% | SCHEDULE 13D/A |
| 2025-08-19 | John R. Wilson TTE, John R. Wilson Revocable Trust U/A DTD 08/03/2017 | 5.1% | SCHEDULE 13D/A |
| 2025-08-20 | John R. Wilson TTE, John R. Wilson Revocable Trust U/A DTD 08/03/2017 | 4.96% | SCHEDULE 13D/A |
| 2025-11-14 | Alyeska Investment Group, L.P. | 9.9% | SCHEDULE 13G/A |
| 2025-11-17 | New Enterprise Associates 16, L.P. | 9.9% | SCHEDULE 13D/A |
Questions about who owns Marker Therapeutics, Inc.
Who owns Marker Therapeutics, Inc.?
On this page, 2 holders' latest ownership filings report 5% or more of Marker Therapeutics, Inc.: New Enterprise Associates 16, L.P. (9.9%, Schedule 13D/A, filed 2025-11-17) and Alyeska Investment Group, L.P. (9.9%, Schedule 13G/A, filed 2025-11-14).
Who are the largest shareholders of Marker Therapeutics, Inc.?
By the share each holder's latest filing reports, the largest holders of Marker Therapeutics, Inc. on this page are New Enterprise Associates 16, L.P. (9.9%) and Alyeska Investment Group, L.P. (9.9%).
When did New Enterprise Associates 16, L.P. buy into Marker Therapeutics, Inc.?
The filings give report dates, not purchase dates. The earliest filing from New Enterprise Associates 16, L.P. on this page is the Schedule 13D/A, filed 2025-08-18, reporting 12.6%; its latest, Schedule 13D/A filed 2025-11-17, reports 9.9%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 5 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Also on the record for Marker Therapeutics, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| December 30, 2024 | Form D, private offering | $16.10M sold | Form D page | Source |
Tools for this story
Each opens in a new tab, filled in for Marker Therapeutics, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.